Loading...

Eli Lilly and Company

LLYNYSE
Healthcare
Drug Manufacturers - General
$728.25
$16.58(2.33%)

Eli Lilly and Company (LLY) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.
EPS (TTM)
$15.30
P/E Ratio
45.46
ROE
0.88%
Net Margin
0.26%

Key Financial Metrices

Valuation Metrics

4 metrics
Market CapTotal market value of outstanding shares
$658.26B
Shares OutstandingTotal number of shares issued
$946.46M
Book Value/ShareNet worth per share
$20.44
Revenue/ShareAnnual revenue per share
$59.31

Profitability Metrics

6 metrics
EPS (TTM)Earnings per share trailing twelve months
$15.3
Net MarginNet income as percentage of revenue
25.91%
Operating MarginOperating income as percentage of revenue
42.77%
ROEReturn on shareholders' equity
88.36%
ROAReturn on total assets
13.67%
ROCEReturn on capital employed
36.79%

Cash Flow Metrics

3 metrics
Free Cash Flow/ShareCash generated per share after capex
$2.02
Cash/ShareCash and equivalents per share
$3.95
FCF YieldFree cash flow as percentage of market cap
0.28%

Dividend Metrics

2 metrics
Dividend/ShareAnnual dividend payment per share
$5.80
Dividend YieldAnnual dividend as percentage of stock price
0.83%
Financial Ratios Analysis data is not available for LLYFinancial Ratios Analysis details for LLY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Sector Benchmarking data is not available for LLYSector Benchmarking details for LLY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Eli Lilly and Company Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Eli Lilly and Company. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Eli Lilly and Company's unique business strengths and challenges.

Key Financial Metrics for Eli Lilly and Company

For Eli Lilly and Company, essential financial indicators include EPS 15.30, PE 45.46, and ROE 0.88. These key ratios reveal insights into Eli Lilly and Company's profitability, valuation, and operational health. Understanding these metrics enables you to compare Eli Lilly and Company with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Eli Lilly and Company

Metrics like Net Margin 25.91% and ROA 13.67% shed light on how well Eli Lilly and Company is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Eli Lilly and Company can sustain its operations and continue growing in the future.

Valuation and Market Position of Eli Lilly and Company

Using ratios such as P/B Ratio 34.20 and PEG Ratio 1.86, investors can assess whether Eli Lilly and Company is appropriately valued based on its financials and growth potential. These figures, combined with Eli Lilly and Company's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Eli Lilly and Company

Financial health indicators, such as Debt/Equity Ratio 1.87 and Cash Flow $2.02, provide a snapshot of Eli Lilly and Company's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Eli Lilly and Company, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Eli Lilly and Company

Investing in Eli Lilly and Company based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Eli Lilly and Company focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;